Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.58 |
| ▸ | NSD2 | O96028 | 3/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | S100A4 | P26447 | 6/20 | 0.52 |
| ▸ | CDC25B | P30305 | 3/20 | 0.52 |
| ▸ | PTPRC | P08575 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.52 |
| ▸ | PADI1 | Q9ULC6 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033971 | 0.82 | TDP2 (0.58) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL2729738 | 0.77 | TDP2 (0.46) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL29828292 | 0.77 | TDP2 (0.46) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL300666 | 0.77 | TDP2 (0.46) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL460433 | 0.73 | TDP2 (1.00) | TDP2NSD2PAX8TDP1ABL1 | |
| Phanquone SCHEMBL30956643 | 0.73 | MEN1 (1.00) | TDP2NSD2PAX8TDP1ABL1 | |
| Phanquone SCHEMBL462025 | 0.73 | MEN1 (1.00) | TDP2NSD2PAX8TDP1ABL1 | |
| Phanquone SCHEMBL7633567 | 0.73 | MEN1 (1.00) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL5915065 | 0.73 | TDP2 (0.81) | TDP2NSD2PAX8TDP1ABL1 | |
| Phanquone SCHEMBL30659794 | 0.73 | MEN1 (1.00) | TDP2NSD2PAX8TDP1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655301-B1 | CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2015-03-11 | — | — | EP | claimed |
| EP-1655028-B1 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2009-05-13 | — | — | EP | claimed |
| US-20080194501-A1 | Cyclic Bioisosters of Derivatives of a Purine System and Pharmaceutical Composition Based Thereon | ZHILOV, VALERY KHAZHMURATOVICH (RU) | 2008-08-14 | — | — | US | claimed |
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | VALERY KHAZHMURATOVICH ZHILOV (RU) | 2007-06-14 | — | — | US | claimed |
| EP-1655301-A1 | CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | claimed |
| EP-1655028-A2 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | claimed |
| EP-1655301-B1 | CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2015-03-11 | — | — | EP | disclosed |
| US-8592421-B2 | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon | Zhilov, Valery Khazhmuratovich (RU) | 2013-11-26 | — | — | US | disclosed |
| US-7776833-B2 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2010-08-17 | — | — | US | disclosed |
| EP-2074998-A2 | Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2009-07-01 | — | — | EP | disclosed |
| EP-1655028-B1 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2009-05-13 | — | — | EP | disclosed |
| US-20080194501-A1 | Cyclic Bioisosters of Derivatives of a Purine System and Pharmaceutical Composition Based Thereon | ZHILOV, VALERY KHAZHMURATOVICH (RU) | 2008-08-14 | — | — | US | disclosed |
| US-20070166547-A1 | Use of a layer consisting of hydrophobic linear, or two-dimensional polycyclic aromatics as a barrier layer or an encapsulation and electric components constructed with a layer of this type and comprising organic polymers | TECHNISCHE UNIVERSITAT BRAUNSCHWEIG CAROLO-WILHELMINA (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | VALERY KHAZHMURATOVICH ZHILOV (RU) | 2007-06-14 | — | — | US | disclosed |
| EP-1655301-A1 | CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | disclosed |
| EP-1655028-A2 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | ADORA2A, ADORA3, ADORA1 | TDP2 426/4885NSD2 2794/4885PAX8 4604/4885 |
| US-20080194501-A1 | Cyclic Bioisosters of Derivatives of a Purine System and Pharmaceutical Composition Based Thereon | ADORA3, ADORA2A, ADORA2B | TDP2 3261/4885NSD2 4274/4885PAX8 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.